Atrial fibrillation and hypertension: State of the art

##plugins.themes.academic_pro.article.sidebar##

Published Mar 6, 2018
Download
pdf
Vol. 95 No. 7 (2017): Issue Jul 2017

##plugins.themes.academic_pro.article.main##

Soufia Naccache
Mouna Ben Kilani
Rami Tlili
Youssef Ben Ameur
Mohamed Rachid Boujnah

Abstract

Atrial fibrillation and hypertension are often coexistent. Their incidence increases with advancing age and they are responsible for considerable morbidity and mortality. The relation between theses 2 diseases has long been discussed and determined by clinical studies. Left ventricular hypertrophy and left atrial remodeling during hypertension favor the development of atrial fibrillation. AF during hypertension increases the risk of thromboembolic complications and heart failure. In patients with hypertension, pharmacological treatment may control the cardiac structural changes and retard or prevent the occurrence of atrial fibrillation. In case of atrial fibrillation, treatment should be focused on the control of heart rate and rhythm and the prevention of thromboembolic accidents. A strict control of blood pressure is highly required in this situation.



Keywords:

Atrial fibrillation, arterial hypertension, left ventricular hypertrophy, renin-angiotensin-aldosterone system, embolism, heart failure, stroke.

##plugins.themes.academic_pro.article.details##

References

  1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 Oct 16 ; 82.
  2. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013 Oct ; 3:1925-38.
  3. Charlemagne A, Blacher J, Cohen A, Collet JP, Diévart F, de Groote P et al.Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data.Arch Cardiovasc Dis. 2011 Feb ; 104:115-24.
  4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9 ; 285:2370-5.
  5. Levy S, Maarek M, Coumel P, GuizeL,Lekieffre J, Medvedowsky JL et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999 juin ; 99:3028-3035.
  6. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB,Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994 mars ; 271:840-844.
  7. VerdecchiaP, Reboldi G, Gattobigio R, Bentivoglio M,Borgioni C, Angeli F et al. Atrial fibrillation hypertension: predictors and outcome.Hypertension. 2003 Feb; 41:218-223.
  8. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE.The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.Am J Med. 1995 May; 98:476-84.
  9. Wyse DG, Waldo AL, DiMarco JP, et coll; Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) investigators.A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
  10. Van Gelder IC, Hagens VE, Bosker HA et al. for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
  11. Carlsson J, M iketic S, Windeler J et al. for the STAF Investigators . Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am CollCardiol 2003;41:1690-6.
  12. Hohnloser SH, Kuck HH, Lilienthal J for the PIAF Investigators. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF) : a randomized trial. Lancet 2000;356:1789-94.
  13. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest. 2004;126:476 - 486.
  14. Stefano R, Georg N, Yves A. La cardiopathie hypertensive. Forum Med Suisse 2009 ; 9(30-31) :519.
  15. Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target.Am J Cardiol. 2003 May 22 ; 9 :9G-14G.
  16. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults.Circulation. 1997 Oct 7 ; 96:2455-61.
  17. Miller JT, O'Rourke RA, Crawford MH. Left atrial enlargement: an early sign of hypertensive heart disease.Am Heart J. 1988 Oct ; 116:1048-51.
  18. Tedesco MA, Di Salvo G, Ratti G, Natale F, et al. Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study.Clin Cardiol. 2001 Sep ; 24(9) :603-7.
  19. Toh N, Kanzaki H, Nakatani S, Ohara T, et al.Left atrial volume combined with atrial pump function identifies hypertensive patients with a history of paroxysmal atrial fibrillation. Hypertension. 2010 May ; 55(5) :1150-6.
  20. Madu EC, Baugh DS, Gbadebo TD, Dhala A, et al.Effect of ethnicity and hypertension on atrial conduction: evaluation with high-resolution P-wave signal averaging. Clin Cardiol. 2001 Sep ; 24(9) :597-602.
  21. Fukunami M, Yamada T, Ohmori M, Kumagai K, et al. Detection of patients at risk for paroxysmal atrial fibrillation during sinus rhythm by P wave-triggered signal-averaged electrocardiogram.Circulation. 1991 Jan ; 83(1) :162-9.
  22. Loaldi A, Pepi M, Agostoni PG, FiorentiniC,et al. Cardiac rhythm in hypertension assessed through 24 hour ambulatory electrocardiographic monitoring. Effects of load manipulation with atenolol, verapamil, and nifedipine.Br Heart J. 1983 Aug; 50(2):118-26.
  23. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.Neurology. 1978 Oct ; 28(10) :973-7.
  24. Tohgi H, Tajima T, Konno T, Towada S, et al.The risk of cerebral infarction in non-valvularatrial fibrillation: effects of age, hypertension and antihypertensive treatment.Eur Neurol. 1991 ; 31(3) :126-30.
  25. Scardi S, Mazzone C. Impact of chronic atrial fibrillation on cardiovacularmortality.Ital Heart J Suppl. 2000 Sep ; 1(9) :1117-22.
  26. Lakshminarayan K, Anderson DC, Herzog CA, Qureshi AI. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States.Neurologist. 2008 May ; 14(3) :143-50.
  27. Predictors of thromboembolism in atrial fibrillation II: Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators.Ann Intern Med. 1992 Jan 1; 116(1):6-12.
  28. Camm AJ, Lip GY, De Caterina R, Savelieva I, et al. ESCCommitteefor Practice Guidelines-CPG. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.Europace. 2012 Oct ; 14(10) :1385-413.
  29. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure.Cardiovasc Res. 2002 May ; 54(2) :456-61.
  30. Solun B, Marcoviciu D, Dicker D. Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolicstroke.Eur J Intern Med. 2009 Mar ; 20(2) :125-31.
  31. Levy S. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.NatClinPractCardiovasc Med. 2006 Apr ; 3(4) :220-5.
  32. Webster MW, Fitzpatrick MA, Nicholls MG, Ikram H, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure.Am J Cardiol. 1985 Sep 15 ; 56(8) :566-9.
  33. Wachtell K, Gerdts E, Aurigemma GP, Boman K, et al. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.Blood Press. 2010 Jun ; 19(3) :169-75.
  34. McMurray JJ, Young JB, Dunlap ME, Granger CB, et al. CHARM Investigators. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.Am Heart J. 2006 May ; 151(5) :985-91.
  35. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15:36-43.
  36. January CT, Wann LS, Alpert JS, Calkins H, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.J Am CollCardiol. 2014 Dec 2 ; 64(21) :e1-76.